Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Therapy of Metastatic or Recurrent Solid Tumors With BRCA Mutations

• Status: Not yet recruiting
• Trial end date: 2024-03-31

Summary

This phase I/Ib trial studies the side effects and best dose of magrolimab when given in combination with olaparib for the treatment of patients with solid tumor cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or have come back (after a period of improvement) (recurrent) and have mutations in the BRCA1/2 genes. Magrolimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Giving magrolimab and olaparib may work better than olaparib alone or other standard therapies in treating BRCA-mutated metastatic or recurrent solid tumors.

• Phase: Phase 1

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Magrolimab; Olaparib; Poly(ADP-ribose) Polymerase Inhibitors